Clinical Trial: Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06932744) titled 'Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy' on April 10.

Brief Summary: The main purpose of this study is to evaluate the efficacy of MY008211A compared to eculizumab in PNH patients.

Study Start Date: Aug. 30, 2024

Study Type: INTERVENTIONAL

Condition: Paroxysmal Nocturnal Haemoglobinuria (PNH)

Intervention: DRUG: MY008211A tablets

Participants will receive MY008211A at a dose of 400 mg orally b.i.d for 24 weeks

DRUG: Eculizumab Injection

Eculizumab Injection for 24 weeks

Recruitment Status: RECRUITING

Sponsor: Wuhan Creat...